My 'Other Birthday' is Coming Up After Cancer
What it’s like having a “second birthday” after receiving a bone marrow transplant for my AML.
Source: curetoday.com
📰 Agvhd News
Agvhd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Agvhd. Real-time updates on events, politics, business and more.
Valvular Heart Disease Associated With AMD Subset
The subretinal drusenoid deposit form of age-related macular degeneration (AMD) was found to be associated with valvular heart disease as well as cardiac index.
New York United States Liudmila Dutko Mount Sinai School Of Medicine European Journal Mount Sinai School
Source: ajmc.com
Supportive Care and Medication Access in GvHD
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Hana Safah Corey Cutler New Treatment Options Optimizing Care Graft Vs Host Disease Medication Access
Source: onclive.com
First-Line Therapy for Chronic GvHD
Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.
New Treatment Options Optimizing Care Graft Vs Host Disease Online Therapy Chronic Gvhd Chronic Graft Vs Host Disease
Source: onclive.com
Hematologists and Patients Come Together for Patient-Focused GVHD Discussions
Carrie L. Kitco, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.
Vanderbilt University United States Carriel Kitko Sagars Patel Alliance Website Department Of Pediatrics
Source: onclive.com
Patient Case Studies of GvHD
Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.
Optimizing Outcomes Allogeneic Transplants Case Studies Hematologic Malignancies Graft Versus Host Disease Patient Case Studies
Source: onclive.com
Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure
Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
Abbvie Roche Pharmacyclics Janssen First Affiliated Hospital Of Soochow University Experimental Hematology First Affiliated Hospital Soochow University
Source: ajmc.com
Graft-versus-Host Disease Prophylaxis and Management
Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.
Optimizing Outcomes Allogeneic Transplants Host Disease Prophylaxis Hematologic Malignancies Graft Versus Host Disease Graft Versus Host Disease Prophylaxis
Source: onclive.com
Transplant Complications and Survival Outcomes
Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.
Optimizing Outcomes Allogeneic Transplants Hematologic Malignancies Allogeneic Transplant Graft Versus Host Disease Allo Hsct
Source: onclive.com
Acute Versus Chronic Graft-Versus-Host Disease (GVHD)
Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz distinguish acute from chronic graft-versus-host disease (GVHD), how such distinction has changed over the last decades, and provide an overview of consensus definitions for disease grading.
Source: onclive.com